Delcath Systems Inc (DCTH) - News Archive

Targeting Liver Tumors: Delcath Systems Promising Developments in Oncology Delcath Systems, Inc., a leader in the field of interventional oncology, has made significant strides in the ongoing battle against primary and...

In a significant move aimed at bolstering its growth and operational capabilities, Delcath Systems, Inc. (Nasdaq: DCTH), a pioneering interventional oncology company focused on innovative treatments for primary and meta...

QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH) continues to demonstrate its commitment to fostering industry-leading talent as part of its broader strategy to advance treatments for primary and metastatic liver c...

Delcath Systems, Inc.: Advancements in Liver Cancer Treatment and Strategic Employment Inducements Delcath Systems, Inc. (NASDAQ: DCTH), based in Queensbury, New York, is carving a significant niche in the interventiona...

QUEENSBURY, N.Y. In an assertive move to bolster its talented roster, Delcath Systems, Inc. (Nasdaq: DCTH), a leading interventional oncology company dedicated to the treatment of primary and metastatic cancers of the l...

Promising New Data from Delcath Systems Highlights Efficacy of HEPZATO KIT in Treating Metastatic Uveal Melanoma SubgroupsIn a significant development for the oncology community, Delcath Systems, Inc. (Nasdaq: DCTH), an...

In the ever-evolving landscape of cancer treatment, few companies are making as significant an impact as Delcath Systems, Inc. (Nasdaq: DCTH). Based in Queensbury, New York, Delcath has emerged as a leading player in in...

In an era where precision medicine and innovative therapies are shaping the landscape of oncology, Delcath Systems, Inc. has emerged as a harbinger of hope for patients grappling with liver tumors. The company, based in...

QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH), a leading interventional oncology company steadfast in its mission to treat primary and metastatic cancers of the liver, has announced the issuance of an equity awa...

Delcath Systems Reports Q2 2024 Results: Revenue Growth and Continued Focus on Liver Cancer Treatment QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology firm specializing in therapies for...

Delcath Systems Secures NTAP Approval from CMS for HEPZATO KIT: A Milestone in Liver Cancer Treatment QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH), a pioneering interventional oncology company, announced that i...

QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH), an innovative interventional oncology company specializing in the treatment of both primary and metastatic cancers of the liver, has proudly announced its participa...

Delcath Systems Announces Martha S. Rook as New Chief Operating OfficerNEW YORK, March 18, 2024 - Delcath Systems, Inc., a leading interventional oncology company specializing in the treatment of primary and metastatic...

Delcath Systems Inc., a New York-based interventional oncology company dedicated to the treatment of primary and metastatic liver cancers, marked a substantial milestone with the launch and first commercial utilization...